Drugs during pregnancy

Drugs During Pregnancy

Volumn , Issue , 2009, Pages 1-484

  Kallen, Bengt ^a  

^a UNIVERSITY OF LUND   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892210322     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (368)

1. Warkany J. Environmental teratogenic factors. In: Fishbein M (ed): First International Conference on Congenital Malformations. Lippincott, Philadelphia and Montreal, pp 99-105.
2. Wiedemann H-R. Hinwise auf eine derzeitige Haufung hypo-und aplastischer Fehlbildungen der Gliedmassen. Med Welt 1961; 37: 1863-1866.
3. Lenz W. Kindliche Misbildungen nach Medikament-Einnahme während der Gravidität? Dtsch Med Wochenschr 1961; 86: 2555-2556.
4. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 2: 1358.
5. Källén B. Methodological issues in the epidemiological study of teratogenicity of drugs. Congen Anomal 2005; 45: 44-51.
6. Meadow SR. Congenital abnormalities and anticonvulsant drugs. Proc Roy Soc Med 1968; 63: 12-49.
7. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982; 2: 937.
8. Sørensen HT, Steffensen FH, Olesen C, Nielsen GL, Pedersen L. Pregnancy outcome in women exposed to calcium channel blockers. Reprod Toxicol 1998; 12: 383-384.
9. Rosa F. Databases in the assessment of the effects of drugs during pregnancy. J Allergy Clin Immunol 1999; 103: S360-361.
10. Oberlander TF, Warburton W, Misri S, Ahgajanian J, Hertzman C. Neonatal oucomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63: 898-906.
11. Heinonen OP, Slone D, Monson RR, Hook EB, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Inc., Littleton, Mass.
12. Bártfai Z, Kocsis J, Puhó EH, Czeizel AE. A population-based case-control teratologic study of promethazine use during pregnancy. Reprod Toxicol 2008; 25: 276-285.
13. Norstedt Wikner B, Stiller C-O, Bergman U, Asker C, Källén B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Safety 2007; 16: 1203-1210.
14. Laegreid L, Olegård R, Walström J, Conradi N. Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr 1989; 114: 126-131.
15. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
16. Miettinen OS. Simple interval estimation of risk ratio. Am J Epidemiol 1974; 100: 515-516.
17. Heinonen OP, Slone D, Monson RR, Hook EB, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Inc., Littleton, Mass.
18. Mahadevan U, Kane S. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131: 283-311.
19. Nelson MM, Forfar JO. Associations bewen drugs administered during pregnancy and congenital abnormalities in the foetus. BMJ 1971; I: 523-527.
20. Diav-Citrin O, Arnon J, Shechtman S, Schaefer C, van Tonningen MR, Celmenti M, de Santis M, Robert-Gnansia E, Valti E, Malm H, Ornoy A. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther 2005; 21: 269-75.
21. Källén B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol 1998; 105: 877-81.
22. Källén BA. Use of omeprazole during pregnancy no hazard demonstrated in 955 infants exposed during pregnancy. Eur J Obstet Gynecol Reprod Biol 2001; 96: 63-8.
23. Mahadevan U, Kane S. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131: 283-311.
24. Ruigómez A, García Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Wallander MA, Johansson S. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 1999; 150: 476-81.
25. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in pregnancy. Publishing Sciences Group, Inc. Littleton, Mass. 1977.
26. Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005; 61: 899-906.
27. Berkovitch M, Mazzota P, Greenberg, Elbirt D, Addis A, Schuler-Faccini L, Merlob P, Arnon J, Stahl B, Magee L, Moretti M, Ornoy A. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. Am J Perinatol 2002; 19: 311-316.
28. Sørensen HT, Nielsen GL, Christensen K, Tage-Jensen U, Ekbom A, Baron J & the Euromap study group. Birth outcome following maternal use of metoclopramide. Br J Clin Pharmacol 2000; 49: 264-268.
29. Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koren G. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG 2004; 111: 940-943.
30. Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Europ J Clin Pharmacol 2005; 61: 899-906.
31. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in pregnancy. Publishing Sciences Group, Inc. Littleton, Mass. 1977.
32. Mahadevan U, Kane S. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131: 283-311.
33. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in pregnancy. Publishing Sciences Group, Inc. Littleton, Mass. 1977.
34. Mahadevan U, Kane S. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131: 283-311.
35. Schwethelm B, Margolis LH, Miller C, Smith S. Risk status and pregnancy outcome among Medicaid recipients, Am J Prev Med 1989; 5: 157-163.
36. Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, Koren G. Prospective, controlled, multicentre study of loperamide in pregnancy. Can J Gastroenterol 2000; 14: 185-187.
37. Heetun Z, Byrnes C, Neary P, O'Morain C. Review article: reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Therapeut 2007; 26: 513-533.
38. Diav-Citrin O, Park YH, Veerasuntharam G, Polacheck H, Bologa M, Pastuszak A, Koren G. The safey of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterol 2007; 102: 1406-1413.
39. Nørgård B, Pedersen L, Christensen LA, Sørensen HT. Therapeutic drug use in women wih Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406-1413.
40. Källén B, Nilsson E, Otterblad Olausson P. Maternal use of loperamide in early pregnancy and delivery outcome. Acta Paediatr 2008; 97: 541-545.
41. Ramzi F, Elias D, Mona S, Zreik TG. Sibutramine in pregnancy. Europ J Obst Gynecol Reprod Biol 2005; 122: 243-244.
42. Kadioglu M, Ulku C, Yaris F, Kesim M, Kalyoncu NI, Yaris E. Sibutramine use in pregnancy: report of two cases. Birth Def Research (A) 2004; 70: 545-546.
43. Einarson A, Bonari L, Sarkar M, McKenna K, Koren G. Exposure to sibutramine during pregnancy: case series. Europ J Obst Gynecol Reprod Biol 2004; 116: 142.
44. De Santis M, Straface G, Cavaliere B, Caruso A. Early first-trimester sibutramine exposure: pregnancy outcome and neonatal follow-up. Drug Saf 2006; 29: 255-259.
45. Heinonen OP, Slone D, Monson RR, Hook EB, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishin Sciences Group, Inc. Littleton, MA.
46. Åberg A, Westbom L, Källén B. Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev 2001; 61: 85-95.
47. Correa A, Gilboa SM, Besser Lm, Botto LD, Moore CA, Hobbs CA, Cleves MA, Riehle-Colarusso TJ, Waller DK, Reece EA. Diabetes mellitus and birth defects, Am J Obst Gynecol 2008; 199: 237.el-9.
48. Bell R, Bailey K, Cresswell T, Hawthorne G, Critchley J, Lewis-Barned N, on behalf of the Northern Diabetic Pregnancy Survey Steering Group. BJOG. Trends in prevalence and outcomes of pregnancy in women with pre-existing type I and type II diabetes. 2008; E-publication before print: DOI: 10, 1111/j.1471-0528.2007.01644.x. 445-452.
49. Allen VM, Armson BA, Wilson RD Allen VM, Blight C, Gagnon A, Johnson JA, Langlois S, Summers A, Wyatt P, Farine D, Armson BA, Crane J, Delisle MF, Keenan-Lindsay L, Morin V, Schneider CE, Van Aerde J: Teratogenicity associated with preexisting and gestational diabetes. J Obstet Gynaecol Can 2007; 29: 927-944.
50. Frías JL, Frías JP, Frías PA, Martínez Frías ML. Infrequently studies congenital anomalies as clues to the diagnosis of maternal diabetes mellitus. Amer J Med Genet Part A. 2007; 143A: 2904-2909.
51. Mulinare J, Cordero JF, Erickson JD, Berry RS. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988; 260: 3141-5.
52. Milunsky A, Jick H, Jick SS, Bruell CJ, Maclaughlin DA, Rothman KJ, Willett W. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989; 262: 2847-52.
53. Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995; 6: 219-26.
54. Botto LD, Khoury MJ, Mulinare J, Erickson JD. Periconceptional multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case-control study. Pediatrics 1996; 98: 911-7.
55. Werler MM, Cragan JD, Wasserman CR, Shaw GM, Erickson JD, Mitcell AA. Multivitamin supplementation and multiple births. Am J Med Genet 1997; 71: 93-6.
56. Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal mulitivitamin use. Am J Epidemiol 2000; 151: 878-84.
57. Rothman KJ, Moore LL, Singer MR, Nguyen US, Mannino S, Milunsky A. Teratogenicity of high vitamin A intake. N Engl J Med 1995; 333: 1369-73.
58. Botto LD, Loffredo C, Scanlon KS, Ferencz C, Khoury MJ, David Wilson P, Correa A. Vitamin A and cardiac outflow tract defects. Epidemiology 2001; 12: 491-6.
59. Mills JL, Simpson JL, Cunningham GC, Conley MR, Rhoads GG. Vitamin A and birth defects. Am J Obstet Gynecol 1997; 177: 31-6.
60. Miller RK, Hendrickx AG, Mills JL, Hummler H, Wiedand UW. Periconceptional vitamin A use: how much is teratogenic? Reprod Toxicol 1998; 12: 75-88.
61. Mastroiacovo P, Mazzone T, Addis A, Elephant E, Carlier P, Vial T, Gaarbis H, Robert E, Ornoy A, Finardi A, Schaffer C, Caramelli L, Rodrígues-Pinilla E, Clementi M. High vitamin A intake in early pregnancy and major malformations: a multicenter prospective controlled study. Teratology 1999; 59: 7-11.
62. Johansen AM, Lie RT, Wilcox AJ, Andersen LF, Drevon CA. Maternal dietary intake of vitamin A and risk of orofacial clefts: A population-based case-control study in Norway. Amer J Epidemiol 2008; 167: 1164-1170.
63. Schardein JL. Congenital abnormalities and hormones during pregnancy: A clinical review. Teratology 1980; 22: 251-270.
64. Kerber IJ, Warr OS 3rd, Richardson C. Pregnancy in a patient with a prosthetic mitral valve. Associated with a foetal anomaly attributed to warfarin sodium. JAMA 1968: 203: 223-225.
65. Barr M, Burdi AR. Warfarin-associated embryopathy in a 17-week-old abortus. Teratology 1976; 14: 129-34.
66. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68: 122-40.
67. Iturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarías A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986; 315: 1390-3.
68. van Driel D, Wesseling J, Sauer PJ, Touwen BC, van de Veer E, Heymans HS. Teratogen update: Foetal effects after in utero exposure to coumarins, overview of cases, follow-up findings, and pathogenesis. Teratology 2002; 66: 127-40.
69. Cotrufo M, De Feo M, De Santo LS, Romano GP, Della Corte A, Renzulli A, Gallo C. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002; 99: 35-40.
70. Vitale, N, de Feo M, de Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999; 33: 1637-1641.
71. Stevenson RE, Buron OM, Ferlauto GJ, Taylor HA. Hazards of oral anticoagulants during pregnancy. JAMA 1980; 243: 1549-1551.
72. Wesseling J, van Driel D, Smrkovsky M, ven der Veer E, Geven-Boere LM, Sauer PJ, van der Veer E. Neurological outcome in school-age children after in utero exposure to coumarins. Early Hum Dev 2001; 63: 83-95.
73. van Driel D, Wesseling J, Rosendaal FR, Odlink RJ, van der Veer E, Gerver WJ, Geven-Boere LM, Sauer PJ. Growth until puberty after in utero exposure to coumarins. Am J Med Genet 2000; 95: 438-443.
74. Oakley CM. Anticoagulation and pregnancy. Europ Heart J 1995; 16: 1317-1319.
75. Demers C, Derzko C, David M, Douglas J. Society of Obstetricians and Gynaecologists of Canada. Gynaecological and obstetric management of women with inherited bleeding disorders. Int J Gynaecol Obstet 2006; 95: 75-87.
76. Kalter H. Folic acid and human malformations: a summary and evaluation. Reprod Toxicol 2000; 14: 463-476.
77. Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995; 6: 219-226.
78. Källén B, Otterblad Olausson P. Use of folic acid and delivery outcome: a prospective registry study. Reprod Toxicol 2002; 16: 327-332.
79. Källén B. Congenital malformations in infants whose mothers reported the use of folic acid in early pregnancy in Sweden. A prospective population study. Cong Anomal 2007; 47: 119-124.
80. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131-137.
81. Czeizel AE, Dudás I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327: 1832-1835.
82. Berry RJ, Zi Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong LY, Gindler J, Hong SX, Correa A. Prevention of neural tube defects with folic acid in China. N Engl J Med 1999; 341: 1485-1490.
83. Besser LM, Williams LJ, Cragan JD. Interpreting changes in the epidemiology of anencephaly and spina bifida following folic acid fortification of the U.S. grain supply in the setting of long-term trends, Atlanta, Georgia, 1968-2003. Birth Def Res (Part A) 2007; 79: 730-736.
84. Rosano A, Smithells D, Cacciani L, Botting B, Castilla E, Cornel M, Erickson D, Goujard J, Irgens I, Merlob P, Robert E, Siffel C, Stoll C, Sumivochi Y. Time trends in neural tube defects prevalence in relation to preventive strategies: an international study. J Epidemiol Comm Health 1999; 53: 630-635.
85. Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Amer J Med Genet Part C 2004; 125C: 12-21.
86. Molloy AM, Kirke PN, Brody LC, Scott JM, Mills JL. Effects of folate and vitamin B12 deficiencies during pregnancy on fetal, infant and child development. Food Nutr Bull 2008; 29 (2 Suppl): 101-111.
87. Ray JG, Blom HJ. Vitamin B12 insufficiency and the risk of fetal neural tube defects. Q J Med 2003; 96: 289-295.
88. Verkleij-Hagoort AC, van Driel LMJW, Lindemans J, Isaacs A, Steegers EAP, Helbing WA, Uittrlinden AG, Steegers-Theunissen RPM. Genetic and lifestyle factors related to the periconception vitamin B12 status and congenital heart defects: A Dutch case-control study. Mol Genet Metabol 2008; 94: 112-119.
89. Källén B, Lundberg G, Åberg A. Relationship between vitamin use, smoking, and nausea and vomiting of pregnancy. Acta Obst Gynecol Scand 2003; 82: 916-920.
90. Siu SC, Colman JM, Alvarez AN, Mercier L-A, Morton BC, Kells CM, Beergin L, Kiess MC, Marcotte F, Taylor DA, Gordon EP, Spears JC, Tam JW, Amankwah KS, Smallhorn JF, Farine D, Sørensen S. Prospective multicenter study of pregnancy outcomes in women with heart disease. Ciculation 2001; 104: 515-421.
91. Ford AA, Wylie BJ, Waksmonski CA, Simpson LL. Maternal congenital cardiac disease. Outcomes of pregnancy in a single tertiary care center. Obstet Gynecol 2008; 112: 828-833.
92. Iung B. The valve patient and pregnancy. Expert Rev Cardiovasc Ther 2008; 6: 1249-1258.
93. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Littleton, Mass. 1977.
94. Rey E, Couturier A (1994) The prognosis of pregnancy in women with chronic hypertension. Am J Obst Gynecol 181: 410-416.
95. McCowan LM, Buist RG, North RA, Gamble G. (1996) Perinatal morbidiy in chronic hypertension. Br J Obstet Gynecol 103: 123-129.
96. Sibai BM, Caritis SN, Hauth JC, MacPherson C, VanDorsten JP, Klebanoff M, Landon M, Paul RH, Meis PJ, Modovnik M, Dombrowski MP, Thurnau GR, Moawad AH, Roberts J. (2000) Preterm delivery in women with pregestational diabetes or chronic hypertension relative to women with uncomplicated pregnancies. The National Institute of Child Health and Human Development-Fetal Medicine Units Network. Am J Obst Gynecol 183: 1520-1524.
97. Ray JG, Burrows RF, Burrows E et al (2001) McMaster outcome study of hypertension in pregnancy. Early Human Develop 64: 129-143.
98. Abalos E, Duley L, Steyn DW, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. (2007) Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews Issue 1. Art.No.: CD002252, DOI: 10.1002/14651858.CD002252.pub2.
99. Heinonen OP, Slone D, Shapiro S (1977) Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Inc. Littleton, Mass.
100. Källén B, Otterblad Olausson P (2003) Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 17: 255-261.
101. Cooper WO, Hernandez-Diaz S, Arbogast P et al (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. New Engl J Med 354: 2443-2451.
102. Weber-Schoendorfer C, Hannemann D, Mester R, Eléfant E, Cuppers-Maarschalkerweerd B, Arnon J, Vial T, Rodriguez-Pinilla E, Clementi M, Robert-Gnansia E, de Santis M, Malm H, Dolivo A, Schaefer C. The safety of calcium channel blockers during pregnancy: A prospective, multicenter, observational study. Reprod Toxicol 2008; 26: 24-30.
103. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group Inc., Littletone, MA. 1977.
104. Manson JM, Freyssinges C, Ducrocq MB, Stephenson WP. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 1996; 10: 439-446.
105. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Amer J Med Genet 2004; 131A: 287-298.
106. Petersen EE, Mitchell AA, Carey JC, Werler MW, Louik C, Rasmussen SA, and the National Birth Defects Prevention Study. Maternal exposure to statins and risk for birth defects: A case-series approach. Amer J Med Genet 2008: 146A: 2701-2705.
107. Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Def Res (Part A) 2007; 73: 888-896.
108. Taguchi N, Rubin ET, Hosokawa A, Choi J, Ying AY, Moretti ME, Koren G, Ito S. Prenatal exposure to HMG-CoA reductase inhibitors: Effects on foetal and neonatal outcomes. Reprod Toxicol 2008; 26: 175-177.
109. Ofori B, Rey E, Bérard A. Risk of congenital anomalies in pregnant users of statin drugs. Brit J Clin Pharmacol 2007; 64: 496-509.
110. Nelson MM, Forfar JO. Associations between drugs administered during pregnancy and congenital abnormalities of the foetus. Br Med J 1971; 1: 523-7.
111. Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream. Lanceet 1992; 339: 687.
112. Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet 1993; 341: 1352-1353.
113. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet 1993; 341: 1181-1182.
114. Shapiro L Pastuszak A, Curto G, Koren G. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet 1997; 350: 1143-1144.
115. Loureiro K, Kao KK, Jones KL, Alvarado S, Chavez C, Dick L, Felix R, Johnson D, Chambers CD. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Amer J Med Gener 2005; 136A: 117-121.
116. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix Jr AW, Lott IT, Richard JM, Sun SS. Retinoic acid embryopathy. New Engl J Med 1985; 313: 837-841.
117. Bérard A, Azoulay L, Koren G, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol 2007; 63: 196-205.
118. Geiger JM, Baudin M, Saurat JH. Teratogenic risk with etretinate and acitretin treatment. Dermatology 1994; 189: 109-116.
119. de DieSmulders CEM, Surkenboom MCJM, Veraart J, van Karwijk C, Sastrowijoto P, van der Linden E. Severe limb defects and craniofacial anomalies in a fetus conceived during acitretin therapy. Teratology 1995; 52: 215-219.
120. Barbero P, Lotersztein V, Bronberg R, Perez M, Alba L. Acitrein embryopathy: A case report. Birth Def Res (Part A) 2004; 70: 831-833.
121. Lam J, Poliftka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008; 59: 295-315.
122. Edwards MJ, Agho KA, Attia J, Diaz P, Hayes T, Illingworth A, Roddick LG. Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy. Amer J Med Genet 2003; 120A: 459-463.
123. Carmichael SI, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ, for the National Birth Defects Prevention Study. Maternal corticosteroid use and orofacial clefts. Amer J Obst Gynecol 2007; 197: 585.e1-585.e7.
124. Mygind H, Thulstrup AM, Pedersen L, Larsen H. Risk of intrauterine growth retardation, malformations and other birth outcomes in children after topical use of corticosteroids in pregnancy. Acta Obst Gynecol Scand 2002; 81: 234-239.
125. Kaler SG, Patrinos ME, Lambert GH, Myers TF, Karlman R, Anderson CL. Hypertrichosis and congenital anomalies associated with maternal use of minoxidil. Pediatrics 1987; 79: 434-436.
126. Smorlesi C, Caldarella A, Caramelli L, Di Lotto S, Moroni F. Topically applied minoxidil may casue fetal malformation: a case report. Birth Def Res (Part A) 2003; 67: 997-1001.
127. Rosa FW, Baum C, Shaw M. Pregnancy outcomes after first-trimester vaginities drug therapy. Obster Gynecol 1987; 69: 751-755.
128. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obst Gynecol 1995; 172: 525-529.
129. Caro-Patón T, Carvajal A, de Diego IM, Martín-Arias LH, Requejo AA, Rodriguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997; 44: 179-182.
130. Kazy Z, Puhó E, Czeizel AE. The possible association between the combination of vaginal metronidazole and miconazole treatment and poly-syndactyly. Poplation-based case-control teratologic study. Reprod Toxicol 2005; 20: 89-94.
131. Kazy Z, Puhó E, Czeizel AE. Teratogenic potential of vaginal metronidazole treatment during pregnancy. Europ J Obst Gynecol 2005; 123: 174-178.
132. Czeizel AE, Tóth M, Rockenbauer M. No teratogenic effect after clotrimazole therapy during pregnancy. Epidemiology 1999; 10: 437-440.
133. Czeizel AE, Fladung B, Vargha P. Preterm birth reduction after clotrimazole treatment duriing pregnancy. Eur J Obst Gynecol 2004; 116: 157-163.
134. Czeizel AE, Rockenbauer M. A population-based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynecol 1998; 105: 322-327.
135. Sørensen HT, Larsen H, Jensen ES, Thulstrup AM, Schønheyder HC, Nielsen GL, Czeizel A and the EUROMAP Study Group. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J Antimicrobial Chemother 1999; 44: 854-855.
136. Diav-Citrin O, Schechtman S, Gotteiner T, Arnon J, Ornoy A. Pregnancy outcome after gestational exposure to metronidazole: a prospective cohort study. Teratology 2001; 63: 186-192.
137. Weil C. The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 1986; 10: 172-195.
138. Krupp P, Monka C. Bromocriptine in pregnancy; safety aspects. Klin Wochenschr 1987; 65: 823-827.
139. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996; 10: 333-337.
140. Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A, Rocchi F, Gangi E, Paracchi S, Landi ML, Beck-Peccoz P, Bonati M. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002; 16: 791-793.
141. Janerich D T, Piper JM, Glebatis DM. Oral contraceptives and birth defects. Amer J Epidemiol 1980; 112: 73-79.
142. Harlap S, Shiono PH, Ramcharan S. Congenital abnormalities in the offspring of women who used oral and other contraceptives around the time of conception. Int J Fertility 1985; 30: 39-47.
143. Pardthaisong T, Gray RH. In utero exposure to steroid contraceptives and outcome of pregnancy. Amer J Epidemiol 1991; 134: 795-803.
144. Li D-K. Daling JR, Mueller BA, Hickok DE, Fantel AG, Weiss NS. Oral contraceptive use after conception in relation to the risk of congenital urinary tract anomalies. Teratology 1995; 51: 30.36.
145. Källén B, Mastroiacovo P, Lancaster PAL, Mutchinick O, Kringelbach M, Martínez-Frías ML, Robert E, Castilla EE. Oral contraceptives in the etiology of isolated hypospadias. Contraception 1991; 44: 173-182.
146. Lejeune J, Prieur M. Contracéptives oroux et trisomie 21. Ann Génet 1979; 22: 61-66.
147. Ericson A, Källén B, Lindsten J. Lack of correlation between contraceptive pills and Down's syndrome. Acta Obst Gynecol Scand 1983; 62: 511-514.
148. Källén B. Maternal use of oral contraceptives and Down syndrome. Contraception 1989: 39: 503-506.
149. Ahn HK, Choi JS, Han JY, Kim MH, Chung JH, Ryu HM, Kim MY, Yang JH, Koong MK, Nava-Ocampo AA, Koren G. Pregnancy outcome after exposure to oral contraceptives during the periconceptional period. Human Exp Toxicol 2008; 27: 307-313.
150. Mittendorf R. Teratogen update: carcinogenesis and teratogenesis associated with exposure to dietylstilbestrol (DES) in utero. Teratology 1995; 51: 435-445.
151. Heinonen OP, Slone D, Monson RR, Hook EB, Shapiro S. Cardiovascular birth defects and anteenatal exposure to female sex hormones. New Engl J Med 1977; 296: 67-70.
152. Aarskog D. Maternal progestins as a possible cause of hypospadias. New Engl J Med 1979; 300: 75-78.
153. Calzolari E, ContieroMR, Roncatari E, Mattiuz PL, Volpato S. Aetiological factors in hypospadias. J Med Genet 1986; 23: 333-337.
154. Harris EL. Genetic epidemiology of hypospadias. Epidemiol Rev 1990; 12: 29.40.
155. Källén B, Martínez-Frías ML, Castilla EE, Robert E, Lancaster PAL, Kringelbach M, Mutchinick OM, Mastroiacovo P. Hormone therapy during pregnancy and isolated hypospadias: an international case-control study. Int J Risk Safety Med 1992; 3: 183-198.
156. Dudás I, Gidai J, Czeizel AE. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Cong Anomal 2006; 46: 194-198.
157. Källén B, Finnström O, Nygren KG, Otterblad Olausson P, Wennerholm U-B. In vitro fertilization in Sweden: obstetric charactristics, maternal morbidity and mortality. BJOG 2005; 112: 1529-1535.
158. Källén B, Finnström O, Nygren KG, Otterblad Olausson P. In vitro fertilization (IVF) in Sweden: Risk for congenital malformations after different IVF methods. Birth Def Res (Part A) 2005; 73: 162-169.
159. Hack M, Brish M, Serr DM, Insler V, Salomy M, Lunenfeld B. Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after clomiphene therapy. JAMA 1970; 220: 1329-1333.
160. Ash H, Greenblatt RB. Update on the safety and efficiency of clomiphene citrate as a therapeutic agent. J Reprod Med 1976; 17: 175-180.
161. Ahlgren M, Källén B, Rannevik G. Outcome of pregnancy after clomiphene therapy. Acta Obst Gynecol Scand 1976; 55: 371-375.
162. MacGregor AH, Schardein JL. Congenital anomalies and hormones during pregnancy. A critical revies. Teratology 1980; 7: 199-202.
163. Greenland S, Ackerman DL. Clomiphene citrate and neural tube defects: A pooled analysis of controlled epidemiological studies and recommendations for future studies. Fertil Steril 1995; 64: 936-941.
164. Källén B, Otterblad Olausson P, Nygren KG. Neonatal outcome in pregnancies from ovarian stimulation. Obstet Gynecol 2002; 100: 414-419.
165. Farhi J, Fisch B. Risk of major congenital malformations associated with infertility and its treatment by extent of iatrogenic intervention. Pediatr Endocrinol Rev 2007; 4: 352-357.
166. Elizur SE, Tulandi T. Drugs in infertility and fetal safety. Fertil Steril 2008; 89: 1595-1602.
167. Källén B, Finnstrom O, Nygren KG, Otterblad Olausson P. In vitro fertilization (IVF) in Sweden: Risk for congenital malformations after different IVF methods. Birth Def Res (Part A) 2005; 73: 162-169.
168. Källén B, Carlsson SS, Bengtsson BK. Diabetes insipidus and use of desmopressin (Minirin) during pregnancy. Eur J Endocrinol 1995; 132: 144-146.
169. Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998; 53: 450-455.
170. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Ksapinovic S, Chang D, Diav-Citrin O, Chitayat D, Nulman I, Einarson TR, Koren G. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385-392.
171. Pradat P, Robert-Gnansia E. di Tanna GL, Rosano A, Lisi A, Mastroiacovo P, and ll contributors to the MADRE database. Frist trimester exposure to corticosteroids and oral clefts. Birth Def Res (Part A) 2003; 67: 968-970.
172. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004; 18: 93-101.
173. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ for the National Birth Defects Prevention Study. Maternal corticosteroid use and orofacial clefts. Am J Obst Gynecol 2007; 197: 585e1-585.e7.
174. Norstedt Wikner B, Skjöldebrand Sparre L, Stiller C-O, Källén B, Asker C. Maternal use of thyroid hormones in pregnancy and neonatal outcome. Acta Obst Gynecol 2008; 87: 617-627.
175. Milham S, Elledge D. Maternal methimazole and congenital defects in children. Teratology 1972; 5: 125.
176. Clementi M, Di Gianantonio E, Pelo E, Mammi I, Brasile RT, Tenconi R. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet 1999; 83: 43-6.
177. DiGianantonio E, Schaefer C, Mastroiacovo P, Cournot MP, Benedicenti F, Reuvers M, Occupati B, Robert E, Bellemin B, Addis A, Arnon J, Clementi M. Adverse effects of prenatal methimazole exposure. Teratology 2001; 64: 262-6.
178. Ferraris S, Valenzise M, Lerone M, Divizia MT, Rosaia L, Blaid D, Nemelka O, Ferrero GB, Silengo M. Malformations following methimazole exposure in utero: An open issue. Birth Defects Research Part A 2003; 67: 989-92.
179. Barbero P, Ricagni C, Mercado G, Bronberg R, Torrado M. Choanal atresia associated with prenatal methimazole exposure: three new patients. Am J Med Genet A 2004; 129: 83-6.
180. Li Z, Ren A, Liu J, Pei L, Zhang L, Guo Z, Li Z. Maternal flu or fever, medication use, and neural tube defects: a population-based case-control study in Northern China. Birth Def Res (Part A) 2007; 79: 295-300.
181. Sánchez A, Rogers R, Sheridan PJ. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol 2004; 43: 709-715.
182. Schardein JL. Chemially Induced Birth Defects, Revised and Expanded. Marker Dekker Ltd, 3Rev Ed. 2000.
183. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. The teratogenic risk of trimethoprim-sulfonamides: a population-based case-control study. Reprod Toxicol 2001; 15: 637-646.
184. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. A population-based case-control teratologic study of ampicillin treatment during pregnancy. Am J Obst Gynecol 2001; 185: 140-147.
185. Dencker BB, Larsen H, Jensen ES, Schønheyder HC, Nielsen GL, Sørensen HT. Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero. Clin Microbiol Infect 2002; 8: 196-201.
186. Jepsen P, Skriver MV, Floyd A, Lipworth L, Schønheyder HC, Sørensen HT. A population-based study of maternal use of amoxicillin and pregnancy outcome in Denmark. Br J Pharmacol 2003; 55: 216-221.
187. Cooper WO, Hernandez-Diaz A, Arbogast PG, Dudley JA, Dyer SM, Gideon PS, Hall KS, Kaltenbach LA, Ray WA. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Ped Perinat Epidemiol 2008; 23: 18-28.
188. Källén BAJ, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003; 17: 255-261.
189. Källén BAJ, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol 2005; 20: 209-214.
190. Bar-Oz B, Diav-Citrin O, Shechtman S, Tellem R, Arnon J, Francetic I, Berkovitch M, Ornoy A. Prgnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study. Europ J Obst Gynecol Reprod Biol 2008; 141: 31-34.
191. Wogelius P, Nørgaard M, Gisham M, Pedersen L, Schønheyder HC, Sørensen HT. Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones. Int J Antimicrob Agents 2005; 26: 323-326.
192. Schaefer C, Amoura-Elefant E, Vial T, Ornoy A, Garbis H, Robert E, Rodriguez-Pinilla E, Pexieder T, Prapas N, Merlob P. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obst Gynecaol Reprod Biol 1996; 69: 83-89.
193. Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, Schick B, Bonati M, Moretti M, Lalkin A, Pastuszak A, Koren G. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicr Agents Chemother 1998; 1336-1339.
194. Czeizel A, Puhó EH, Kazy Z. The use of data set of the Hungarian case-control surveillance of congenital abnormalities for evaluation of birth outcomes beyond birth defects. Cent Eur J Public Health 2007; 15: 147-153.
195. Lopez-Rangel E, van Allen MI: Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth Def Res (Part A) 2005; 73: 919-923.
196. Mastroiacovo P, Mazzone T, Botto LD, Serafini MA, Finardi A, Caramelli L, Fusco D. Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am J Obst Gynecol 1996; 175: 1645-1650.
197. Sørensen HT, Nielsen GL, Olesen C, Larsen H, Steffensen FH, Schønheyder HC, Olse J, Czeizel AE. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br J Clin Pharmacol 1999; 48: 234-238.
198. Nørgaard M, Pedersen L, Gislum M, Erichsen R, Søgaard KK, Schønheyder HC, Sørensen HT. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study. J Antimicr Chemother 2008; 62: 172-176.
199. Bar-Oz B, Moretti ME, Bishai R, Mareels G, van Tittelboom T, Verspeelt J, Koren G. Pregnancy outcome after in utero exposure to itraconazole: a prospective study. Am J Obst Gynecol 2000; 183: 617-620.
200. Schardein JL. Chemically induced birth defects. Marcel Dekker, Inc. New York and Basel. 1985, p. 375.
201. Steen JS, Stainton. Ellis DM. Rifampicin in pregnancy. Lancet 1977; II: 604-605 (Letter).
202. Brost BC, Newman RB. The maternal and foetal effects of tuberculosis therapy. Obst Gynecol Clin North Am 1997; 24: 659-673.
203. Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Bown Z, Alexander ER, Andrews EB. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the International Acyclovir Pregnancy Registry, 1984-1999. Birth Defects Res (Part A) 2004; 201-207.
204. Ratanajamit C, Vinther Skriver M, Jepsen P, Chongsuvivatwong V, Olsen J, Sørensen HT. Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study. Scand J Infect Dis 2003; 35: 244-259.
205. White A, Eldridge R, Andrews E. Birth outcomes following zidovudine exposur in pregnant women: the Antiretroviral Pregnancy Registry. Acta Paediatr Scand 1997; 421: 86-88.
206. Newschaffer CJ, Cocroft J, Anderson CE, Hauck WW, Turner BJ. Prenatal zidovudine use and congenital anomalies in a Medicaid population. J Acquir Immune Defic Syndr 2000; 24: 249-256.
207. Murdaca G, Constantini S, Villa R, Setti M, Puppo F, Indiveri F. A case of transposition of the great arteries in a female infant of a HIV-1-infected woman. Potential teratogenic effects of antiretroviral drugs. Intern Emerg Med 2006; 1: 86-88
208. Watts DH, Li D, Handelsman E, Tilson H, Paul M, Foca M, Vajaranant M, Diaz C, Tuomala R, Thompson B. Assessment of birth defects according to maternal therapy among infants in the women and infants transmission study. J Acquir Immune Defic Syndr 2007; 44: 299-305.
209. Ross L. Congenital anomalies in two infants born after gestational gamma-globulin prophylaxis. Acta Paediatr 1995; 84: 1436-7.
210. Brent RL. Risks and benefits of immunizing pregnant women: The risk of doing nothing. Reprod Toxicol 2006; 21: 383-389.
211. Namael MH, Zlaee M, Naseh N. Congenital rubella syndrome in infants of women vaccinated during or just before pregnancy with measles-rubella vaccine. Indian J Med 2008; 127: 551-554.
212. Minussi L, Mohrdieck R, Bercini M, Ranleri T, Sanseverino MT, Momino W, Callegari-Jacques SM, Schuler-Faccini I. Prospective evaluation of pregnant women vaccinated against rubella in soutehrn Brazil. Reprod Toxicol 2008; 25: 120-123.
213. Robert E, Vial T, Schaefer C, Arnon J, Reuvers M. Exposure to yellow fever vaccine in early pregnancy. Vaccine 17: 283-285, 1999.
214. Suzano CES, Amaral E, Sato HK, Papaiordanou PM. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 2006; 24: 1421-1426.
215. Ryan MA, Seward JF; Smallpox Vaccine in Pregnancy Registry Team. Pregnancy, birth, and infant health oucomes from the National Smallpox Vaccine in Pregnancy Registry, 2003-2006. Clin Infect Dis 2008; 46 (Suppl. 3): 5221-5226.
216. Ryan MA, Gumbs GR, Conlin AM, Sevick CJ, Jacobson IG, Snell KJ, Spooner CN, Smith TC; Department of Defense Birth and Infant Health Registry. Evaluation of preterm births and birth defects in liveborn infants of US military women who received smallpos vaccine. Birth Defect Res (Part A) 2008; 82: 533-539.
217. Harjulehto-Mervaala T, Aro T, Hillesmaa VK, Hovi T, Saxén H, Saxén L. Oral polio vaccination during pregnancy: lack of impact on foetal development and perinatal outcome. Clin Infect Dis 1994; 18: 414-420.
218. Ryan M, Smith TC, Sevick CJ, Honner WK, Loach RA, Moore CA, Erickson JD. Birth defects among infants born to women who received anthrax vaccine in pregnancy. Am J Epidemiol 2008; 168: 434-442.
219. Czeizel AE, Rockenbauer M. Tetanus toxoid and congenital abnormalities. Int J Gynecol Obst 1999; 64: 253-258.
220. D'Acremont V, Tremblay S, Genton B. Impact of vaccines given during pregnancy on the offspring of women consulting a travel clinic: A longitudinal study. J Travel Med 2008; 15: 77-81.
221. Schardein J. Chemically Induced Birth Defects. Marcel Dekker, Inc. New York and Basel, 1985.
222. Østensen M. Antirheumatische Therapie und Reproduktion. Z Rheumatol 2006; 65: 217-224.
223. Sandberg-Wohlheim M, Frank D, Goodwin TM, Giesser B, Lopez-Bresnahan M, Stam-Moraga M, Chang P, Francis GS. Pregnancy outcome during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005; 65: 802-806.
224. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 2005; 65: 807-811.
225. Exposure to interferon during pregnancy. Prescrire Int 2007; 16: 22.
226. Jain AB, Reyes J, Marcos A, Mazariegos G, Eghtesad B, Fontes PA, Cacciarelli TV, Marsh JW, de Vera ME, Rafail A, Fung JJ. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation 2003; 76: 827-832.
227. Bar-Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome afer cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71: 1051-1055.
228. Källén B, Westgren M, Åberg A, Otterblad Olausson P. Pregnancy outcome after maternal organ transplantation in Sweden. BJOG 2005; 112: 904-909.
229. Pisoni CN, D'Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf 2008; 7: 219-222.
230. Carey JC, Martinez L, Balken E, Leen-Mitchell M, Robertson J. Determination of human teratogenicity by the astute clinician method: Review of illustrative agents and a proposal of guidelines. Birth Defects Res (Part A) 2009; 85: 63-68.
231. Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, Malm H, Reuvers-Lodewijks ME, Rost can Tonningen-van Driel MM, Arnon J, Ornoy A, Clementi M, di Gianantonio E, Koren G, Braunstein R, Berkovitch M. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res (Part A) 2007; 79: 696-701.
232. Langagergaard V, Pedersen L, Gislum M, Nørgard B, Sørensen HT. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: A Danish nationwide cohort study. Aliment Pharmacol Ther 2007; 25: 73-81.
233. Cleary BJ, Källén B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Def Res (Part A) 2009; 85: 647-654.
234. Nielsen GL, Sørensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroid anti-inflammatory drugs: population based observational study and case-control study, BMJ 2001; 322: 266-269.
235. Ericson A, Källén BAJ. Nonsteoidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001; 15: 371-375.
236. Ofori B, Oracichi D, Blais, Rey E, Bérard A. Risk of congenital anomalies in pregnant users of non-steroidal anti-inflammatory drugs: A nested case-control study. Birth Defect Res (Part B) 2006; 77: 268-279.
237. Werler MM, Mitchell AA, Shapiro S. First trimester medication use in relation to gastroschisis. Teratology 1992; 45: 361-367.
238. Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJ. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996; 54: 84-92.
239. Källén B. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac J 2003; 40: 6224-628.
240. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother 2006; 40: 824-829.
241. Boubred F, Vendemmia M, Garcia-Meric P, Buffat C, Millet V, Simeoni U. Effects of maternally administered drugs on the foetal and neonatal kidney. Drug Saf 2006; 29: 397-419.
242. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Inc. Littleton, MA.
243. Rabinovitch O, Zemer D, Kukia E, Sohar E, Mashiach S. Colchicine treatment in conception and pregnancy: two hudred thirty-one pregnancies in patients with familial Mediterranean fever. Am J Reprod Immunol 1992; 28: 245-246.
244. Barkenstadt M, Weisz B, Cuckle H, Di-Castro M, Guetta E, Barkai G. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever, Am J Obst Gynecol 2005; 193: 1513-1516.
245. Ferreira NR. Frota-Pessoa O. Trisomy after colchicine treatment. Lancet 1969; 1: 1161-2.
246. Djokanovic N, Klieger-Grossman C, Koren G. Does treatment with biphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 2008; 30: 1146-1148.
247. James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes. Obstet Gynecol Surv 2008; 63: 49-57.
248. Heinoen, OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Inc. Littleton, MA.
249. Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction 2004; 99: 209-214.
250. Kozer E, Nikfar S, Costei A, Boskivic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital malformations: a meta-analysis. Am J Obst Gynecol 2002; 187: 1623-1630.
251. Nørgård B, Puhó E, Czeizel A, Skriver MV, Sørensen HT. Aspirin use during early pregnancy and the risk of congenital abnormalities: A population-based case-control study. Amer J Obst Gynecol 2005; 192: 922-923.
252. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002; 155: 26-31.
253. Rebordosa C, Kogevinas M, Horváth-Puhó A, Nørgård B, Morales M, Czeizel AE, Vilstrup H, Sørensen HT, Olsen J. Acetaminophen use during pregnancy: effects on risk for congenital abnormalities. Amer J Obst Gynecal 2008; 198: 178e1-178.e7.
254. Bar-Oz B, Clementi M, Di Giantonio E, Greenberg R, Beer M, Merlob P, Arnon J, Ornoy A, Zimmerman DM, Berkovitch M. Matamizol (dipyrone, optalgin) in pregnancy, is it safe? A prospective comparative study. Europ J Obstet Gynecol Reprod Biol 2005; 119: 176-179.
255. Ács N, Bánhidy F, Puhó E, Czeizel AE. A possible dose-dependent teratogenic effect of ergotamine. Reprod Toxicol 2006; 22: 551-552.
256. Heinonen OP. Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Scoences Group, Inc. Littleton, MA. 1977.
257. Källén B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001; 41. 351-356.
258. Reiff-Eldridge R, Heffner CR, Aphross SA, Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Amer J Obst Gynecol 2000; 182: 159-163.
259. Olesen C, Hald Steffensen F, Sørensen HT, Lauge Nielsen G, Olsen J. Pregnancy outcome following prescription for sumatriptan. Headache 2000; 40: 20-24.
260. Fox AW, Chambers CD, Anderson PO, Diamond ML, Spierings EL. Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache 2002; 42: 8-15.
261. Evans EW, Lorber KC. Use of 5-HT1 agonists in pregnancy. Ann Pharmacother 2008; 42: 543-549.
262. Janz D, Fuchs U. Sind antiepileptische Medikamente während der Schwangerschaft schädlich? Deutch Med Wschr 1964; 89: 241-243.
263. Meadow SR. Congenital abnormalities and anticonvulsant drugs. Proc Roy Soc Med 1970; 63: 48-49.
264. Wide K, Winbladh B, Tomson T, Källén B. Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25 years. Epilepsia 2000; 41: 854-861.
265. Hanson JW, Myrianthopoulos NC, Sedgwick Harvey MA, Smith DW. Risks to the offspring of women treated with hydantoid anticonvulsants, with emphasis on the foetal hydantoin syndrome. J Pediatr 1976; 89: 662-668.
266. Adab N, Tudor Smith C, Vinten J, Williamson PR. Winterbottom JB. Common antiepileptic drugs in pregnancy in women with epilepsy (Review). Cochrane Library number CD004848. The Cochrane Library 2008; issue 1: 1-38.
267. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defect. Lancet 1982; ii: 937.
268. Källén AJB. Maternal carbamazepine and infant spina bifida. Reprod Toxicol 1994; 8: 203-205.
269. Harden CL. Antiepileptic drug teratogenesis: what are the risks for congenital malformations and adverse cognitive outcomes? Int Review Neurobiol 2008; 83: 205-213.
270. Meador KJ, Bakeer GA, Browning N, Clayton-Smith J, Combs-Cantrell D, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW for the NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. New Engl J Med 2009; 360: 1597-1605.
271. Nguyen HT, Sharna V, McIntyre RS. Teratogenesis associated with antibipolar agents. Adv Ther 2009. E-pub ahead of print.
272. Hagell P, Odin P, Vinge E. Pregnancy in Parkinson's disease: a review of the literature and a case report. Mov Disord 1999; 13: 34-38.
273. Rumeau-Rouqette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1977; 15: 57-64.
274. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Sciences Group, Inc. Littleton, MA. 1977.
275. Diav-Citrin O, Schechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, Clementi M, Ornoy A. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. I Clin Psychopharm 2005; 66: 317-322.
276. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002; 63 (Suppl. 4): 42-55.
277. McKenna, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson A. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005; 66: 444-449.
278. Yeshayahu Y. The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities. Amer J Psychiatry 2007; 164: 1759-1760.
279. Coppola D, Russo LJ, Kwarta RF Jr, Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007; 30: 247-264.
280. Newharn JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Willians, RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparative study. B J Psych 2008; 192: 333-337.
281. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophrenia Bull 2008: E-publ, Doi: 10.1093/schul/sbn107.
282. Reis M, Källén B. Maternal use of antipsycotics in early pregnancy and delivery outcome. J Clin Pharmacology 2008; 28: 279-288.
283. Moore JA. An assessment of lithum using the IEHR Evaluative Process for Assessing Human Developmental and Reproductive Toxicity of Agents. IEHR Expert Scientific Committee. Reprod Toxicol 1999; 9: 175-210.
284. Schou M, Goldfield MD, Weinstein MR, Villeneuve A. Lithium and pregnancy. I. Report from the Register of Lithium Babies. BMJ 1973;ii: 135-136.
285. Källén B, Tandberg A. Lithium and pregnancy. A cohort study on manic-depressive women. Acta psych Scand 1983; 68: 134-139.
286. Yacobi S, Ornoy A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review. Isr J Psychiatry Relat Sci 2008; 45: 95-106.
287. Rementia JL, Bhatt K. Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J Pediatr 1977; 90: 123-126.
288. Gillberg G. "Floppy infant syndrom" and maternal diazepam. Lancet 1977; ii: 244.
289. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998; 317: 839-43.
290. Laegreid L, Olegård R, Wahlström J, Conradi N. Abnormalities in children exposed to benzodiazepines in utero. Lancet 1987; 1: 108-9.
291. Laegreid L, Hagberg G, Lundberg A. The effect of benzodiazepines on the fetus and the newborn. Neuropediatrics 1992; 23: 18-23.
292. Bonnot O, Vollset SE, Godet PF, D'Amato T, Robert E. In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam? Encephale 2003; 29: 553-559.
293. Diav-Citrin O, Oktore B, Lucarelli K, Koren G. Pregnancy outcome following first-trimester exposure to zoplicone: a prospective controlled cohort study. Am J Perinatol 1999; 16: 157-160.
294. Norstedt Wikner B, Stille C-O, Källén B, Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Safety 2007; 16: 1-7.
295. Norstedt Wikner B, Stille C-O, Källén B, Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Safety 2007; 16: 1203-1210.
296. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, Gardner A, Hom M, Koren G. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246-2248.
297. McElhatton PR, Gaarbis HM, Eléfant E, Vial T, Bellemin B, Mastroiacovo P, Arnon J, Rodrígues-Pinilla E, Schaefer C, Pexieder T, Merlob P, dal Verme S. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996; 10: 285-294.
298. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055-2061.
299. Oberlander TF, Warburton W, Misri S, Aghajanian J, Herzman C. Neonatal outcomes after prenatal exposure to selective seotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63: 898-906.
300. Louik C, Lin AE, Werler MM, Hernández-Dáz S, Mitchell A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. New Engl J Med 2007; 356: 2675-2683.
301. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM for the National Birth Defets Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defecs. New Engl J Med 2007; 356: 2684-2692.
302. Ericson A, Källén B, Wiholm B-E. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 503-508.
303. Källén B, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Def Res (A) 2007; 79: 301-308.
304. Källén B. The safety of antidepressant drugs during pregnancy. Exper Opin Drug Saf 2007; 6: 357-370-
305. Pearlstein T. Perinatal depression: treatment options and dilemmas. J Psychiatry Neurosci 2008; 33: 302-318.
306. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetiine. Arch Pediatr Adolesc Med 2002; 156: 1129-1132.
307. Källén B. Neonate charcteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312-316.
308. Chambers CD, Hernandez-Diaz S, van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med 2006; 354: 579-587.
309. Källén B, Otterlad Olausson P. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepid Drug Safety 2008; 17: 801-806.
310. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livinston J, Boudreau SM, Smith DH, Davis RL, Willy ME, Platt R. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharacoepid Drug Safety 2009; 18: 246-252.
311. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernánderz-Díaz S. Selective serotonin reuptake inhibitor used and risk of gestational hypertension. Am J Psychiatry Epub 2009. DOI 10.1176/appi.ajp.2008.08060817.
312. Dayan J, Creveuil C, Marks MN, Conroy S, Herlicoviez M, Dreyfus M, Tordjman S. Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosom Med 2006; 68: 938-946.
313. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepid Drug Safety 2007; 16: 1075-1085.
314. Källén B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. (Letter) Reprod Toxicol 2006; 21: 221-222.
315. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SA, Smith D, Yood MU, Platt R. For the HMO Research Network Center for Education in Therapeutics. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy, Pharmacoepidem Drug Safety 2007; 16: 1086-1094.
316. Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE. Externalizing and attentional behaviors in children of depressed mothers treated with a selective reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007; 161: 22-29.
317. Polizzi A, Huson SM, Vincent A. Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology 2000; 62: 332.341.
318. Gaither KH, Brunner Huber LR, Thomson ME, Huet-Hudson YM. Does the use of nicotine replacement therapy during pregnancy affect pregnancy outcomes? Matern Child Health J E-publ 2008. DOI 10.1007/s10995-008-0361-1.
319. Strandberg-Larsen K, Tinggaard M, Nybo Andersen A-M, Olsen J, Grønbaek M. Use of nicotine replacement therapy during pregnancy and stillbirth: a cohort study. BJOG 2008; E-publ 2008: DOI10.1111/j.1471-0528.01867x.
320. Morales-Suárez-Varela MM, Bille C, Christensen K, Olsen J. Smoking habits, nicotine use, and congenital malformations. Obstet Gynecol 2006; 107: 51-57.
321. Pauly JR, Slotkin TA. Maternal tobacco smoking, nicotine replacement and neurobehavioural development. Acta Paediatrica 2008; 97: 1331-1337.
322. Rayburn WF, Bogenschutz MP. Pharmacotherapy for pregnant women with addictions. Amer J Obst Gynecol 2004; 191: 1885-1897.
323. McCarthy JJ, Leamon MH, Stenson G, Biles LA. Outcomes of neonates conceived on methadone maintenance therapy. J Subst Abuse Treatm 2008; 35: 202-206.
324. Costedoat-Chalumeau N, Amoura Z, Duhaut P. Huong DLT, Sebbough D, Wechslaer B, Vauthier D, Denjoy I, Lupoglazoff J-M, Piette J-C. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Arthritis Rheumatism 2003; 48: 3207-3211.
325. Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, Frassi M, Biasini C, Zatti S, Chirico G. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2005; 25: 86-89.
326. Borba EF, Turrini-Filho JR, Kuruma KA, Bertola C, Pedalini ME, Lorenzi MC, Bonfá E. Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. Lupus 2004; 13: 223-227.
327. Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, de Vries A, Chongsuphajaisiddhi T, White NJ. The effects of mefloquine treatment in pregnancy. Clin Infect Dis 1999; 28: 808-815.
328. Vanhauwere B, Maradit H, Kerr L. Post-marketing surveillance of prophylactic mefloquine (Lariam®) use in pregnancy. Am J Trop Med 1998; 58: 17-21.
329. Phillips-Howard PA, Steffen R, Kerr L, Vanhauwere B, Schildknecht J, Fuchs E, Edwards R. Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. J Travel Med 1998; 5: 121-126.
330. Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health 2003; 8: 488-56.
331. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608-1614.
332. de Silva NR, Sirisena JL, Gunasekera DP, Ismail MM, de Silva HJ. Effect of mebendazole therapy during pregnancy and birth outcome. Lancet 1999; 353: 1145-1149.
333. Diav-Citrin O, Schechtman S, Arnon J, Lubart I, Ornoy A. Pregnancy outcome after gestational exposure to mebendazole: a prospective controlled cohort study. Am J Obstet Gynecol 2003; 188: 282-285.
334. Ács N, Bánhidy F, Puhó E, Czeizel A. Population-based case-control study of mebendazole in pregnant women for birth outcomes. Cong Anomalies 2005; 45: 85-88.
335. Christian P, Khatry S, West KP. Antenatal anthelmintic treatment, birthweight, and infant survival in rural Nepal. Lancet 2004; 364: 981-983.
336. Savioli L, Crompton DWT, Neira M. Use of anthelminthic drugs during pregnancy. Am J Obstet Gynecol 2003; 188: 5-6.
337. Kennedy D, Hurst V, Konradsdottir E, Einarson A. Pregnancy outcome following exposure to permethrin and use of teratogen information. Am J Perinatol 2005; 22: 87-90.
338. Mytton OT, McGready R, Lee SJ, Roberts CH, Ashley EA, Carrara VI, Thwai KL, Jay MP, Wiangambun T, Singhasivanon P, Nosten F. Safety of benzyl benzoate lotion and permethrin in pregnancy: a retrospective matched cohort study. BJOG 2007; 114: 582-587.
339. Heinonen OP. Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton (MA): Publishing Sciences Group, Inc; 1977.
340. Werler MM. Teratogen update: Pseudoephedrine. Birth Def Res (Part A) 2006; 76: 445-452.
341. Werler MM, Bosco JL, Shapira SK, National Birth Defects Prevention Study. Maternal vasoactive exposure, amniotic band, and terminal transverse limb defects. Birth Def Res (Part A) 2009; 85: 52-57.
342. Feldkamp ML, Carey JC, Sadler TW. Development of gastroschisis: Review of hypotheses, a novel hypothesis, and implications for research. Amer J Med Genet (Part A) 2007; 143A: 639-652.
343. Källén B, Otterblad Olausson P. Use of oral decongestants during pregnancy and delivery outcome. Am J Obst Gynecol 2006; 194: 480-485.
344. Tan KS, Thomson NO. Asthma in pregnancy. Am J Med 2000; 109: 727-733.
345. Chambers C. Safety of asthma and allergic medications in pregnancy. Immunol Allergy Clin North Amer 2006; 26: 13-28.
346. Murphy VE, Clifton VL, Gibson PG. Asthma exacerbations during pregnancy: incidence and association with pregnancy outcome. Thorax 2006; 61: 169-176.
347. Källén B. The safety of asthma medications during pregnancy. Expert Opinion Drug Saf 2007; 6: 15-26.
348. Tata LJ, Lewis SA, McKeever TM, Smith CJP, Doyle P, Smeeth L, Gibson JE, Hubbard RB. Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring; a UK population-based study. Thorax 2008; 63: 981-987.
349. Bakhireva L, Jones KL, Schatz M, Klonoff-Cohen HS, Johnson D, Slymen DJ, Chambers CD; Organization of Teratology Information Specialists Collaborative Research Group. Asthma control during pregnancy and the risk for preterm delivery or impaired fetal growth. J Allergy Clin Immunol 2007; 119: 618-625.
350. Blais L, Beauchesne M-F, Rey É, Malo J-L, Forget A. Use of inhaled corticosteroids during the first trimester of prgnancy and the risk of congenital malformations among women with asthma. Thorax 2007; 62: 320-328.
351. Lin S, Munsie JPW, Hardt-Losavio ML, Bell E, Druschel C, Romitti PA, Oley R and the National Birth Defects Prevention Study. Maternal asthma mediation use and the risk of gastroschisis. Am J Epidemiol 2008; 168: 73-79.
352. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 1. Maternal characteristics, pregnancy and delivery complications. Europ J Pharmacol 2007; 63: 363-373.
353. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 2. Infants characteristics excluding congenital malformations. Europ J Pharmacol 2007; 63: 375-381.
354. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants. Europ J Pharmacol 2007; 63: 383-388.
355. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Publishing Scineces Group, Inc. Littleton (MA). 1977.
356. Martínez-Frás M-L, Rodrígues-Pinilla E. Epidemiologic analysis of prenatal exposure to cough medicines containing dextramethorphan: no evidence of human teratogenicity. Teratology 2001; 63: 38-41.
357. Einarson A, Lyszkiewicz D, Koren G. The safety of dextromethorphan in pregnancy. Chest 2001; 119: 466-469.
358. Bateman DN, McElhatton PR, Dickinson D, Wren C, Matthews JNS, O'Keeffe M, Thomas SHL. A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England. Eur J Clin Pharmacol 2004; 60: 635-641.
359. Seto A, Einarson T, Gideon K. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol 1997; 14: 119-124.
360. Källén B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Maternal-Foetal Neonat Med 2002; 11: 146-152.
361. Brent BL. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Reprod Toxicol 1995; 9: 337-349.
362. Källén B, Otterblad Olausson P. Monitoring of maternal drug use and infant congenital malformations. Does loratadine cause hypospadias? Int J Risk Safety Med 2001; 14: 115-119.
363. Källén B, Otterblad Olausson P. No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy. Int J Med Sci 2006; 3: 106-107.
364. Webet-Schoendorfer C, Schaefer C.The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol 2008; 26: 19-23.
365. Källén B, Mottet I. Delivery outcome after the use of meclozine in early pregnancy. Europ J Epidemiol 2003; 18: 665-669.
366. Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005; 61: 899-906.
367. Ballard PD, Hearney EF, Smith MB. Comparative teratogenicity of selected glucocorticoids applied ocularly in mice. Teratology 1977; 16: 175-180.
368. Kwon YH, Fingert JH, Kuehn MH, Alward WLM. Primary open-angle glaucoma. New Engl J Med 2009; 360: 1113-1124.